P670: ABSENCE OF BTK, BCL2, AND PLCG2 MUTATIONS IN RELAPSING CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AFTER FIRST-LINE TREATMENT WITH FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V)
L. J. Croner,
J. N. Allan,
N. Jain,
J. F. Seymour,
K. Eckert,
L. W. K. Cheung,
E. Szafer-Glusman
Affiliations
L. J. Croner
1 AbbVie, North Chicago, IL
J. N. Allan
3 Weill Cornell Medicine, New York, NY
N. Jain
4 MD Anderson Cancer Center, Houston, TX, United States of America
J. F. Seymour
5 Peter MacCallum Cancer Center & Royal Melbourne Hospital, Melbourne, VIC, Australia
K. Eckert
2 Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA
